1. The substance P (NK1) receptor antagonist L-760735 inhibits fear conditioning in gerbils
- Author
-
J.K. Webb, A. Fisher, Susan Boyce, Nadia M.J. Rupniak, and Smith David W
- Subjects
Male ,medicine.medical_specialty ,Morpholines ,Venlafaxine ,Substance P ,Amygdala ,Cellular and Molecular Neuroscience ,chemistry.chemical_compound ,Neurokinin-1 Receptor Antagonists ,Internal medicine ,Conditioning, Psychological ,medicine ,Animals ,Fear conditioning ,Ibotenic Acid ,Pharmacology ,Fluoxetine ,business.industry ,Antagonist ,Fear ,Peptide Fragments ,medicine.anatomical_structure ,Endocrinology ,Anti-Anxiety Agents ,chemistry ,Anesthesia ,Female ,NK1 receptor antagonist ,Gerbillinae ,business ,Diazepam ,medicine.drug - Abstract
The ability of the substance P (NK(1) receptor) antagonist (SPA) L-760735 to inhibit conditioned fear was assessed in gerbils using a four plate apparatus. Animals that had been treated with diazepam (3 mg/kg) or L-760735 (3 mg/kg) 30 min before a 3 min conditioning session in the apparatus exhibited a release of plate crossings during the retest session approximately 3 h later. Plate crossings were also increased when animals received diazepam or L-760735 30 min before the retest session. In contrast, fluoxetine and venlafaxine (30 mg/kg) did not exhibit anxiolytic-like effects. During the retest session, gerbils drummed their hind feet on the floor; this behaviour was not observed spontaneously in gerbils that were naïve to the apparatus. Foot drumming was abolished by pretreatment with L-760735 or diazepam (3 mg/kg) but was markedly increased following administration of fluoxetine or venlafaxine (30 mg/kg). Foot drumming elicited by aversive conditioning alone or in combination with fluoxetine was abolished by administration of L-760735 and by amygdala lesions involving the basolateral and lateral nuclei, indicating that this behaviour is an alarm signal or fear response mediated via release of substance P in brain circuits involving the amygdala. The observations provide further evidence for an anxiolytic-like profile of SPAs in preclinical assays and demonstrate a clear difference between the actions of SPAs and established antidepressant drugs.
- Published
- 2003
- Full Text
- View/download PDF